Compare Invesco Solar ETF (TAN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Solar ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Invesco Solar ETF trades at $52.39, while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Invesco Solar ETF nearer its low. Which is the better fit depends on your goals.
| TAN | XBI | |
|---|---|---|
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $73.95 | $164.28 |
52-Week Low | $36.62 | $86.92 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TAN (Invesco Solar ETF) trades at $52.33, up 0.91% with a bearish technical signal from moving averages. The solar ETF faces mixed sentiment as recent Trump administration tariffs on polysilicon imports provide potential tailwinds for U.S. solar manufacturers while regulatory uncertainty and high volatility (beta 1.41) persist. Technical indicators show neutral oscillators with key support at $50 and resistance at $53.
The solar sector outlook is bifurcated between policy-driven opportunities and fundamental challenges. Tariff protections could benefit domestic manufacturers, but high expense ratios (0.7%) and residential solar demand concerns create headwinds. Investment appeal depends on policy stability and the sector's ability to capitalize on growing energy demand from data centers and AI infrastructure.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco Solar ETF
TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
